Phase 1/2 COMPOSE Study of pegtibatinase

Phase 1/2 COMPOSE Study of pegtibatinase

Travere Therapeutics have announced positive topline results from the ongoing Phase 1/2 COMPOSE Study of pegtibatinase, a novel investigational enzyme replacement therapy being evaluated for the treatment of classical homocystinuria (HCU). Read the press release here.

1

0

3868

Phase 1/2 COMPOSE Study of pegtibatinase

1

https://www.hcunetworkaustralia.org.au/phase-1-2-compose-study-of-pegtibatinase/